Craft

Ayala Pharmaceuticals

Stock Price

$0.5

2023-01-27

Market Capitalization

$7.4 M

2023-01-27

Revenue

$692 K

FY, 2022

Ayala Pharmaceuticals Summary

Company Summary

Overview
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined. The company offers AL101 and AL102 gamma-secretase inhibitors, with clinical and nonclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102).
Type
Public
Status
Active
Founded
2017
HQ
Wilmington, DE, US | view all locations
Website
https://www.ayalapharma.com/
Cybersecurity rating
Sectors

Key People

  • Roni Mamluk

    Roni Mamluk, CEO

    • Gary Gordon

      Gary Gordon, Chief Medical Officer

      • Dana Gelbaum

        Dana Gelbaum, Chief Business Officer

        • David Caron

          David Caron, VP CMC

          LocationsView all

          3 locations detected

          • Wilmington, DE HQ

            United States

            1205 N Orange St

          • Wilmington, DE

            United States

            1313 N Market St #5100

          • Rehovot, Center District

            Israel

            Prof. Hillel ve-Khanan Oppenheimer St 4

          Ayala Pharmaceuticals Financials

          Summary Financials

          Revenue (FY, 2022)
          $692.0K
          Gross profit (FY, 2022)
          $90.0K
          Net income (FY, 2022)
          ($38.0M)
          Cash (FY, 2022)
          $2.4M
          EBIT (FY, 2022)
          ($37.5M)
          Enterprise value
          $6.8M

          Footer menu